Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Frequently asked questions
What sector does Pluristem (PSTI) operate in?
Pluristem belongs to the Healthcare sector and operates in the Biotechnology & Medical Research industry.
What is Pluristem (PSTI) current stock price?
As of the latest data, Pluristem stock price is ₪4.96, with a previous close of ₪4.96.
What is Pluristem (PSTI) current market capitalization?
Pluristem market cap is approximately 160.44 million.
What is Pluristem (PSTI) Earnings Per Share (EPS)?
The trailing EPS is -₪1.46.
Does Pluristem (PSTI) pay dividends?
No. Pluristem does not pay a dividend.
What is Pluristem (PSTI) beta (volatility) score?
Pluristem has a beta of 1.913, suggesting it is more volatile than the market.
